Literature DB >> 17641021

Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density.

Raphaëlle Romieu-Mourez1, Moïra François, Marie-Noëlle Boivin, John Stagg, Jacques Galipeau.   

Abstract

Mesenchymal stromal cells (MSC) possess immunosuppressive properties, yet when treated with IFN-gamma they acquire APC functions. To gain insight into MSC immune plasticity, we explored signaling pathways induced by IFN-gamma required for MHC class II (MHC II)-dependent Ag presentation. IFN-gamma-induced MHC II expression in mouse MSC was enhanced by high cell density or serum deprivation and suppressed by TGF-beta. This process was regulated by the activity of the type IV CIITA promoter independently of STAT1 activation and the induction of the IFN regulatory factor 1-dependent B7H1/PD-L1 encoding gene. The absence of direct correlation with the cell cycle suggested that cellular connectivity modulates IFN-gamma responsiveness for MHC II expression in mouse MSC. TGF-beta signaling in mouse MSC involved ALK5 and ALK1 TGF-beta RI, leading to the phosphorylation of Smad2/Smad3 and Smad1/Smad5/Smad8. An opposite effect was observed in human MSC where IFN-gamma-induced MHC II expression occurred at the highest levels in low-density cultures; however, TGF-beta reduced IFN-gamma-induced MHC II expression and its signaling was similar as in mouse MSC. This suggests that the IFN-gamma-induced APC features of MSC can be modulated by TGF-beta, serum factors, and cell density in vitro, although not in the same way in mouse and human MSC, via their convergent effects on CIITA expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641021     DOI: 10.4049/jimmunol.179.3.1549

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  73 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

Review 2.  Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells.

Authors:  Lauren S Sherman; Jessian Munoz; Shyam A Patel; Meneka A Dave; Ilani Paige; Pranela Rameshwar
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

Review 3.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

4.  Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming.

Authors:  Raghavan Chinnadurai; Devi Rajan; Spencer Ng; Kenneth McCullough; Dalia Arafat; Edmund K Waller; Larry J Anderson; Greg Gibson; Jacques Galipeau
Journal:  Blood Adv       Date:  2017-04-25

Review 5.  Immunomodulation by mesenchymal stem cells in veterinary species.

Authors:  Danielle D Carrade; Dori L Borjesson
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

6.  Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro.

Authors:  Lauren V Schnabel; Christian M Abratte; John C Schimenti; M Julia Bevilaqua Felippe; Jennifer M Cassano; Teresa L Southard; Jessica A Cross; Lisa A Fortier
Journal:  Regen Med       Date:  2014-04-28       Impact factor: 3.806

Review 7.  Would cancer stem cells affect the future investment in stem cell therapy.

Authors:  Pranela Rameshwar
Journal:  World J Exp Med       Date:  2012-04-20

8.  Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions.

Authors:  Amir Kol; Soraya Foutouhi; Naomi J Walker; Nguyet T Kong; Bart C Weimer; Dori L Borjesson
Journal:  Stem Cells Dev       Date:  2014-06-26       Impact factor: 3.272

9.  Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis.

Authors:  Moutih Rafei; Elena Birman; Kathy Forner; Jacques Galipeau
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

Review 10.  The role of recipient T cells in mesenchymal stem cell-based tissue regeneration.

Authors:  Yi Liu; Songlin Wang; Songtao Shi
Journal:  Int J Biochem Cell Biol       Date:  2012-08-09       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.